- Home
- BCAX vs MDXG Comparison
BCAX vs MDXG Comparison
Compare BCAX & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAX
- MDXG
- Stock Information
- Founded
- BCAX 2018
- MDXG 2006
- Country
- BCAX United States
- MDXG United States
- Employees
- BCAX N/A
- MDXG N/A
- Industry
- BCAX
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- BCAX
- MDXG Health Care
- Exchange
- BCAX NYSE
- MDXG Nasdaq
- Market Cap
- BCAX 1.3B
- MDXG 1.1B
- IPO Year
- BCAX 2024
- MDXG N/A
- Fundamental
- Price
- BCAX $20.17
- MDXG $7.46
- Analyst Decision
- BCAX Strong Buy
- MDXG Strong Buy
- Analyst Count
- BCAX 4
- MDXG 5
- Target Price
- BCAX $41.00
- MDXG $12.00
- AVG Volume (30 Days)
- BCAX 274.3K
- MDXG 1.0M
- Earning Date
- BCAX 11-12-2024
- MDXG 10-30-2024
- Dividend Yield
- BCAX N/A
- MDXG N/A
- EPS Growth
- BCAX N/A
- MDXG N/A
- EPS
- BCAX N/A
- MDXG 0.52
- Revenue
- BCAX N/A
- MDXG $342,804,000.00
- Revenue This Year
- BCAX N/A
- MDXG $9.56
- Revenue Next Year
- BCAX N/A
- MDXG $9.19
- P/E Ratio
- BCAX N/A
- MDXG $18.44
- Revenue Growth
- BCAX N/A
- MDXG 10.93
- 52 Week Low
- BCAX $18.33
- MDXG $5.47
- 52 Week High
- BCAX $28.09
- MDXG $9.48
- Technical
- Relative Strength Index (RSI)
- BCAX N/A
- MDXG 73.10
- Support Level
- BCAX N/A
- MDXG $5.69
- Resistance Level
- BCAX N/A
- MDXG $7.67
- Average True Range (ATR)
- BCAX 0.00
- MDXG 0.30
- MACD
- BCAX 0.00
- MDXG 0.15
- Stochastic Oscillator
- BCAX 0.00
- MDXG 89.66
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.